ATMI — Q2 2012 Earnings Presentation
9 slides from ATMI's earnings presentation, Jul 25, 2012
Slide 1: Q2 2012 Earnings Teleconference
Q2 2012 Earnings Teleconference July 25, 2012 ¢ Aa |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained herein that relate to ATMI’s future performance, including, without limitation, statements with respect to ATMI’s anticipated results of operations or level of business for 2012 or any other future period, are forward-looking statements within the safe harb
Slide 3: Q2 2012 Financial Summary
Q2 2012 Financial Summary Revenue grew 14% Q/Q and 2% Y/Y > SDS Direct transition complete and meeting expectation > LifeSciences grew 19% on strong consumable growth Improved profitability > Gross margins >50% > 16% operating margins Cash provided by operating activities up 79% Long-term growth out
Slide 4: ATMI consolidated results
ATMI $M (except per share data) Q22012 Q22011 Change Q12012 Change Revenue 105.9 104.0 +2% 92.6 +14% Gross profit 53.5 49.5 +8% 44.2 +21% Gross margin 50.5% 47.5% 47.7% Operating income 16.9 15.4 +10% 6.1 +176% Operating margin 16.0% 14.8% 6.6% Net income 11.4 tal il, 43% 3.9 +195% EPS $0.35 $0.34 $
Slide 5: Diverse revenue mix
Diverse revenue mix Q2 2012 Revenues by Product Q2 2012 Revenues by Sector mlmplant 26% BLogic 56% ™Cu Materials 45% ™ Memory 25% ™ NOWPak 13% ™ Display 8% mlifeSciences 11% m LifeSciences 11% Other 5% @ ATM!
Slide 6: Microelectronics
Microelectronics Q22012 Q22011 Change Q12012 Change Revenue 94.6 94.6 +0% 83.5 +13% Gross margin 52% 50% 50% Operating income 30.5 28.3 +8% 21.0 +45% Operating margin 32.2% 29.9% 25.2% > SDS added $5.8M net revenues and drove gross margin improvement > Display down on lower demand and unfavorable mi
Slide 7: SDS Direct financial summary
SDS Direct financial summary Financial impact per quarter (SM, except EPS) Q42011 —Q12012 Q22012 Revenue Incremental revenue $1.9 $4.5 $7.7 $7 -$8 Inventory repurchase and bum ($8.8) ($7.0) ($1.9) S Net revenue ($6.9) ($2.5) $5.8 $7 - $8 Expense Contract termination $84.6 - = - Incremental operating
Slide 8: LifeSciences
LifeSciences Q22012 Q22011 Change Q12012 Change Revenue 11.2 9.4 +19% O11, +22% Gross margin 38% 27% 32% Operating (loss) (1.1) (1.9) (2.1) Operating margin (9.9%) (19.9%) (23.3%) > Growth in single-use technology is accelerating > Profitability improving with higher mix of consumables > 20-30% CAGR
Slide 9: Thank you for your interest
@O ATM! Thank you for your interest. Troy Dewar Director, Investor Relations 203.207.9349 [email protected]